Cytori Therapeutics, Inc
Cytori Therapeutics, Inc: Cytori Reports 2006 Fourth Quarter and Year-End Results; Reviews 2006 Progress and Provides 2007 Outlook

 
Cytori Therapeutics, Inc. / Final Results 
 
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by 
DGAP – a company of EquityStory AG. 
The issuer is solely responsible for the content of this announcement. 
———————————————————————- 
 
Cytori Therapeutics (NASDAQ: CYTX; Frankfurt: XMPA) reports financial 
results for the quarter and year ended December 31, 2006, reviews 2006 
progress, and provides 2007 outlook. 
 
Cash, cash equivalents and short term investments were $12.9 million as of 
December 31, 2006. Subsequent to the end of the year, Cytori raised $20 
million from an equity offering and entered into an agreement to raise $6 
million as part of a strategic equity agreement with Green Hospital Supply, 
Inc. 
 
Total development revenues for the quarter and year ended December 31, 2006 
were $5.2 million and $6.5 million, respectively, compared to $235,000 and 
$371,000, respectively, for the same period in 2005. The increase in 
development revenues in the fourth quarter and full year 2006 is due to the 
recognition of deferred revenue related to the Olympus-Cytori Joint Venture 
by achieving certain regulatory, preclinical development and Celution™ 
System development milestones. Product revenues from our non-core 
biomaterials products for the quarter and year ended December 31, 2006 were 
$363,000 and $1.5 million, respectively, compared to $858,000 and $5.6 
million for the same periods in 2005. 
 
 
Research and development expenses for the quarter and year ended December 
31, 2006 were $5.2 million and $22.0 million, respectively, compared to 
$4.9 million and $15.5 million, respectively, for the same periods in 2005. 
The increase in R&D for the full year 2006 is attributed to additional 
preclinical studies, preparations for upcoming clinical trials, increased 
Celution™ System development expenses to attain regulatory approvals, and 
internal scale-up for manufacturing of devices and consumables for clinical 
trials. 
 
General and administrative expenses for the quarter and year ended December 
31, 2006 were $2.5 million and $12.5 million, respectively, compared to 
$2.2 million and $10.2 million, respectively, for the same periods in 2005. 
Net loss for the quarter and year ended December 31, 2006 was $1.9 million, 
or $(0.10) per common share, and $25.4 million, or $(1.53) per common 
share. This compares to a net loss of $14.4 million, or $(0.96) per common 
share and $26.5 million, or $(1.80) per common share, respectively, for the 
same periods in 2005. 
 
 
Cytori anticipates achieving the following milestones in 2007:  
 
• Initiate the APOLLO heart attack safety and feasibility trial 
• Announce the outcome of the investigator-initiated breast reconstruction 
safety and feasibility study in Japan; 
• Initiate a multi-center breast reconstruction efficacy trial in Europe in 
patients who underwent partial-mastectomy; 
• Expand the Celution™ System distribution network for reconstructive 
surgery 
• Build out internal Celution™ System manufacturing capabilities to meet 
anticipated product demand in early 2008; 
• Pursue commercialization partners for the Celution™ System in select 
therapeutic areas; and 
• Enter a commercialization agreement for adipose stem cell banking 
 
————————————————————————— 
 
Information and Explaination of the Issuer to this News: 
 
2006 Review 
 
‘In 2006 we made significant strides toward commercializing the Celution™ 
System in early 2008,’ said Christopher J. Calhoun, chief executive officer 
for Cytori. ‘This included the first clinical experience for the Celution™ 
System as part of a breast reconstruction safety and feasibility study, 
attaining key regulatory milestones and adding critical design components 
to tailor the Celution™ System to reconstructive surgery. 
 
‘In addition, we laid extensive groundwork to start two cardiovascular 
disease clinical trials. This included the completion of important 
preclinical research that helped us design and implement controlled, 
randomized dose-escalation studies. Our PRECISE chronic heart disease trial 
began enrollment in January 2007 and our APOLLO acute heart attack trial is 
expected to receive approval and begin enrolling patients next quarter.’ 
 
2007 Outlook  
 
‘Our major 2007 initiatives are to prepare for commercialization, execute 
strategic partnerships and advance our cardiovascular products through 
clinical development,’ added Mr. Calhoun. ‘We believe the buildup to our 
2008 product launch can significantly increase Cytori’s intrinsic value as 
we get closer to generating regenerative medicine product revenues.’ 
 
Conference Call Information  
 
The management of Cytori Therapeutics will host a conference call today at 
10:00 a.m. Eastern Daylight Time (EDT) or 4:00 p.m. Central European Summer 
Time (CEST). The conference call will be webcast live and may be accessed 
under ‘Events & Webcasts’ in the Investor Relations section of the 
Company’s website at http://www.cytoritx.com. The archived version of the 
webcast will be available two hours after the call on the company’s website 
and accessible for 14 days. A telephone replay will be available for one 
week. To access the replay, please call +1 (303) 590-3000 (PIN: 11086131#). 
 
Cautionary Statement Regarding Forward-Looking Statements  
 
This press release includes forward-looking statements regarding events, 
trends and prospects of our business, which may affect our future operating 
results and financial position. Such statements are subject to risks and 
uncertainties that could cause our actual results and financial position to 
differ materially. Some of these risks and uncertainties include our 
history of operating losses, the need for further financing, regulatory 
uncertainties, dependence on performance of third parties, and other risks 
and uncertainties described (under the heading ‘Risk Factors’) in Cytori 
Therapeutics’ Form 10-K annual report for the year ended December 31, 2006. 
We assume no responsibility to update or revise any forward-looking 
statements to reflect events, trends or circumstances after the date they 
are made. 
 
 
 
 
 
DGAP 30.03.2007  
———————————————————————- 
  
Language:     English 
Issuer:       Cytori Therapeutics, Inc. 
              6740 Top Gun Street 
              92121 San Diego, CA Vereinigte Staaten von Amerika 
Phone:        001-858 / 736 5485 
Fax:          001-858 / 458 0994 
E-mail:       sbacher@cytoritx.com 
www:          www.cytoritx.com 
ISIN:         US23283K1051 
WKN:          A0ETV6 
Indices:      PRIMEALL, TECHALLSHARE 
Listed:       Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr 
              in Berlin-Bremen, Stuttgart, München, Düsseldorf 
  
End of News                                     DGAP News-Service 
  
—————————————————————————